US · NUWE
Nuwellis, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Eden Prairie, MN 55344
- Website
- nuwellis.com
Price · as of 2024-12-31
$1.07
Market cap 1.36M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $418.20 | +38,984.11% |
| Intrinsic Value(DCF) | $62.51 | +5,742.06% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | $0.00 | $0.00 | |||
| 2012 | $230,784,122,880.00 | ||||
| 2013 | $294,870,253,568.00 | $14,574,130.15 | $0.00 | ||
| 2014 | $154,473,480,192.00 | $61,789,845,560.36 | $7,705,818,874.03 | $0.00 | $0.00 |
| 2015 | $31,487,399,936.00 | $12,594,959,974.40 | $0.00 | $0.00 | $883,816,573.08 |
| 2016 | $4,679,891,968.00 | $1,962,953,440.00 | $2,517,550,424.29 | $0.00 | $0.00 |
| 2017 | $221,029,200.00 | $168,242,116.80 | $736,090,018,988.16 | $0.00 | $0.00 |
| 2018 | $18,963,000.00 | $7,793,049.47 | $403,965,402,781.84 | $0.00 | $0.00 |
| 2019 | $1,808,100.00 | $730,862.75 | $833,043,912.25 | $0.00 | $0.00 |
| 2020 | $1,205,400.00 | $483,198.38 | $4,194,267.08 | $0.00 | $0.00 |
| 2021 | $132,300.00 | $53,157.26 | $43,947.20 | $0.00 | $0.00 |
| 2022 | $7,820.40 | $22,022.02 | $3,123.68 | $0.00 | $0.00 |
| 2023 | $720.30 | $404.37 | $481.99 | $0.00 | $0.00 |
| 2024 | $54.60 | $418.20 | $64.58 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Nuwellis, Inc.'s (NUWE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $418.20
- Current price
- $1.07
- AI upside
- +38,984.11%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$62.51
+5,742.06% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NUWE | Nuwellis, Inc. | $1.07 | 1.36M | +38,984% | +5,742% | — | — | -6.49 | 11.10 | 8.29 | -6.45 | — | 11.10 | 66.66% | -125.72% | -127.75% | -229.24% | -1021.66% | -113.73% | 0.08 | -1.96 | 3.46 | 2.67 | 0.43 | -9778.00% | -140.00% | -4693.00% | -13.32% | -3.75 | -897.35% | 0.00% | 0.00% | 2.08% | -6.18 | -7.04 | 7.77 | -31.39 |
| ACON | Aclarion, Inc. | $2.74 | 1.59M | +1,150,885% | +444% | — | +8,000,532% | -0.01 | 0.04 | 0.77 | 0.07 | — | -0.11 | -183.81% | -12057.23% | -15293.78% | -5777.80% | 10310.16% | -305.15% | 0.00 | -10.30 | 0.71 | 0.41 | 0.07 | -9062.00% | -3936.00% | 4851.00% | -15922.34% | -4.57 | 10460.70% | 0.00% | 0.00% | 1589.28% | 0.08 | 0.07 | -9.15 | -42.51 |
| BCTXW | BriaCell Therapeutics Cor… | $0.00 | 1.7K | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | -237.76% | -2090.29% | -192.98% | 0.00 | -735.71 | 5.01 | 4.69 | 0.29 | 191519.00% | — | 1459.00% | — | -7.08 | -1560.53% | — | 0.00% | — | — | — | — | — |
| IVF | INVO Fertility, Inc. | $0.95 | 224.52K | +165,168% | +7,886,240% | — | — | -3.04 | 2.17 | 4.23 | -5.15 | -0.62 | -0.96 | 44.00% | -124.40% | -139.25% | -133.37% | -56.16% | -28.01% | 0.78 | -7.69 | 0.07 | 0.05 | -1.28 | 48841.00% | 11625.00% | -3926.00% | -11.43% | -0.17 | -21.88% | 0.00% | 0.00% | 0.00% | -4.53 | -11.65 | 5.63 | -2.40 |
| SABS | SAB Biotherapeutics, Inc. | $4.10 | 39.19M | +213% | -84% | — | +2,692% | -0.44 | 0.58 | 11.35 | 0.04 | — | 0.58 | -262.41% | -3244.87% | -2579.03% | -81.92% | -519.55% | -53.23% | 0.18 | -134.77 | 2.98 | 2.61 | 0.15 | -5183.00% | -4094.00% | 3679.00% | -230.79% | -4.30 | -419.29% | 0.00% | 0.00% | 0.00% | 0.03 | 0.03 | -0.82 | -6.18 |
About Nuwellis, Inc.
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
- CEO
- John L. Erb
- Employees
- 38
- Beta
- -0.11
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($62.51 ÷ $1.07) − 1 = +5,742.06% (DCF, example).